General Information of Drug (ID: DM7U4OT)

Drug Name
ADS-100380 Drug Info
Synonyms ADS-100380; CHEMBL216885; SCHEMBL5904027; BDBM50198221
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44418141
TTD Drug ID
DM7U4OT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [2]
Romidepsin DMT5GNL Cutaneous T-cell lymphoma 2B01 Approved [3]
Panobinostat DM58WKG Chronic graft versus host disease Approved [2]
HBI-8000 DMDWYUN Non-small-cell lung cancer 2C25.Y Registered [4]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [5]
NVP-LAQ824 DM8JWNA Mood disorder 6A60-6E23 Phase 3 [6]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [7]
Phenylbutyrate DMBHPDW Urea cycle disorder 5C50.A Phase 2 [8]
MGCD-0103 DM726HX Non-small-cell lung cancer 2C25.Y Phase 2 [2]
Resminostat DMNE1FR Hepatocellular carcinoma 2C12.02 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase 1 (HDAC1) TT6R7JZ HDAC1_HUMAN Inhibitor [1]

References

1 Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9.
2 Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
3 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
6 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
7 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
8 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
9 2011 Pipeline of 4SC AG.